Company / SG&A per Share
Charles River Laboratories SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$15.10
FY2025
5-year range
$10.40 / $15.10
FY2021-FY2025
Trend
+3.2%
vs FY2024
Sector context
#35 of 157
Health Care
What the data says
Charles River Laboratories's sg&a per share of $15.10 is higher than 78% of companies in the Health Care sector (FY2025). SG&A per Share has increased for 6 consecutive years, from $7.70 in FY2019 to $15.10 in FY2025.
Based on SEC 10-K filings.
15.10 in FY2025 with a 5-year CAGR of +10.7%. Top quartile in the Health Care sector.
Increased from $12.17 to $15.10 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- +10.7%
- 10-Year CAGR
- -
Sector benchmark
-99.9% below sector average
Key checks
Key Insights
- Charles River Laboratories's sg&a per share has grown for 6 consecutive years.
- In FY2025, sg&a per share increased 3.2% year-over-year.
- Ranks #35 out of 157 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.10 | +3.2% |
| FY2024 | $14.63 | +20.2% |
| FY2023 | $12.17 | +16.1% |
| FY2022 | $10.48 | +0.7% |
| FY2021 | $10.40 | +14.7% |
| FY2020 | $9.07 | +17.8% |
| FY2019 | $7.70 | -17.8% |
| FY2018 | $9.36 | +19.5% |
| FY2017 | $7.84 | +0.4% |
| FY2016 | $7.81 | +63.8% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026